Omnicell Inc
NASDAQ:OMCL
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
25.61
53.05
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one OMCL stock under the Base Case scenario is 44.92 USD. Compared to the current market price of 48.89 USD, Omnicell Inc is Overvalued by 8%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Omnicell Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for OMCL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Omnicell Inc
Balance Sheet Decomposition
Omnicell Inc
Current Assets | 1B |
Cash & Short-Term Investments | 570.6m |
Receivables | 251.8m |
Other Current Assets | 188.9m |
Non-Current Assets | 1.3B |
Long-Term Investments | 50.6m |
PP&E | 137.1m |
Intangibles | 931.1m |
Other Non-Current Assets | 173.6m |
Current Liabilities | 961.5m |
Accounts Payable | 47.8m |
Accrued Liabilities | 189.3m |
Other Current Liabilities | 724.4m |
Non-Current Liabilities | 110.7m |
Other Non-Current Liabilities | 110.7m |
Earnings Waterfall
Omnicell Inc
Revenue
|
1.1B
USD
|
Cost of Revenue
|
-623.9m
USD
|
Gross Profit
|
440.3m
USD
|
Operating Expenses
|
-475.8m
USD
|
Operating Income
|
-35.4m
USD
|
Other Expenses
|
17.7m
USD
|
Net Income
|
-17.7m
USD
|
Free Cash Flow Analysis
Omnicell Inc
USD | |
Free Cash Flow | USD |
OMCL Profitability Score
Profitability Due Diligence
Omnicell Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Omnicell Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
OMCL Solvency Score
Solvency Due Diligence
Omnicell Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Omnicell Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OMCL Price Targets Summary
Omnicell Inc
According to Wall Street analysts, the average 1-year price target for OMCL is 47.26 USD with a low forecast of 39.39 USD and a high forecast of 64.05 USD.
Dividends
Current shareholder yield for OMCL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
OMCL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. The company is headquartered in Mountain View, California and currently employs 3,800 full-time employees. The company went IPO on 2001-08-08. The firm is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. The firm's point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The firm's Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility's in-house information management systems. The firm's Central Pharmacy IV Compounding Service offers a range of service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.
Contact
IPO
Employees
Officers
The intrinsic value of one OMCL stock under the Base Case scenario is 44.92 USD.
Compared to the current market price of 48.89 USD, Omnicell Inc is Overvalued by 8%.